Innovative Devices and Futuristic Therapies

Clinical investigators at today’s “Innovative Devices and Futuristic Therapies” session during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, presented 12-month follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days.
The ATLANTA Trial is a first-in-man [...]

Boston Scientific Inc. announced comprehensive data from the TAXUS ATLAS clinical program

Boston Scientific Corporation today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, multi-center, single-arm, historically controlled trials, which evaluate the TAXUS® Liberte® Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. The TAXUS Liberte Stent received U.S. Food and Drug Administration approval on Friday. Results from the [...]

Similarly Low Rates in Patients With Diabetes Compared to Non-Diabetics

Boston Scientific Corporation (NYSE: BSX – News) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS® Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice. The two-year pooled ARRIVE data showed that the TAXUS Stent reduced clinical [...]